Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
Publication year
2017Source
Targeted Oncology, 12, 6, (2017), pp. 815-826ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Medical Oncology
Pathology
Journal title
Targeted Oncology
Volume
vol. 12
Issue
iss. 6
Page start
p. 815
Page end
p. 826
Subject
All institutes and research themes of the Radboud University Medical Center; Radboudumc 9: Rare cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life SciencesThis item appears in the following Collection(s)
- Academic publications [238430]
- Electronic publications [122512]
- Faculty of Medical Sciences [90359]
- Open Access publications [97507]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.